76
|
Austerlitz C, Mota H, Gay H, Campos D, Allison R, Sibata C. On the need for quality assurance in superficial kilovoltage radiotherapy. RADIATION PROTECTION DOSIMETRY 2008; 130:476-481. [PMID: 18325931 DOI: 10.1093/rpd/ncn067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
External auditing of beam output and energy qualities of four therapeutic X-ray machines were performed in three radiation oncology centres in northeastern Brazil. The output and half-value layers (HVLs) were determined using a parallel-plate ionisation chamber and high-purity aluminium foils, respectively. The obtained values of absorbed dose to water and energy qualities were compared with those obtained by the respective institutions. The impact on the prescribed dose was analysed by determining the half-value depth (D(1/2)). The beam outputs presented percent differences ranging from -13 to +25%. The ratio between the HVL in use by the institution and the measurements obtained in this study ranged from 0.75 to 2.33. Such deviations in HVL result in percent differences in dose at D(1/2) ranging from -52 to +8%. It was concluded that dosimetric quality audit programmes in radiation therapy should be expanded to include dermatological radiation therapy and such audits should include HVL verification.
Collapse
|
77
|
Mauri-Llerda JA, Morales-Martínez MD, Salas-Puig J, Vadillo-Olmo FJ, Campos D, Díaz MC, Fernández M, Paz-González JM, Vega-López O, Cobaleda S. [A retrospective study of the effectiveness of lamotrigine in monotherapy for the treatment of epileptic seizures. The ERELMO study]. Rev Neurol 2008; 46:197-202. [PMID: 18330846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
INTRODUCTION The efficacy and tolerability of lamotrigine (LTG) in monotherapy and in combination therapy have been demonstrated in clinical trials. The aim of the ERELMO study was to retrospectively evaluate the effectiveness and safety of LTG, as monotherapy in the control of epileptic seizures in routine clinical practice in Spain. PATIENTS AND METHODS 446 clinical records were selected of patients with LTG treatment in the twelve months previously to the beginning of the study. The main endpoints retrospectively analyzed were effectiveness (percentage of patients with 50% or greater reduction in seizure frequency, improvement in seizure control, percentage of patients remaining-seizure free at 2, 6 and 12 months of LTG monotherapy), and safety (adverse event profile reported and treatment withdrawal). RESULTS The mean age was 41 years old, 57.8% were women. LTG monotherapy treatment (mean maintenance dose was 217.2 mg/day) reduced mean seizure frequency as compared with the basal condition at different study time points (2, 6, 12 months; p < 0.0001). At the end of the study 77% of the patients were seizure free. Loss of treatment effectiveness was shown in 8.5% of patients. Adverse reactions were reported by 15% of patients, the most frequent being insomnia, somnolence, headache and rash. At the end of the study, 88.8% patients were still receiving LTG monotherapy. CONCLUSIONS The present study supports the use of LTG monotherapy due to its effectiveness and good tolerability to promote treatment compliance in usual clinical conditions in patients with epilepsy.
Collapse
|
78
|
Austerlitz C, Mota H, Souza V, Campos D, Gay H, Allison R, Sibata C. SU-FF-T-413: The Response Of The Fricke Dosimeter To Sunlight. Med Phys 2007. [DOI: 10.1118/1.2761138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
79
|
Campos D, Streeper R, Cornell J, Izbicka E. 328 POSTER Rapid, efficient and reproducible SELDI chip robotic preparation method. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70333-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
80
|
Cole J, Streeper R, Campos D, Izbicka E. 327 POSTER Improved method for preparation of formalin-fixed paraffin-embedded tissue for mass spectrometric analysis. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70332-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
81
|
Austerlitz C, Mota H, Souza V, Campos D, Bagnato V, Allison R, Sibata C. SU-FF-T-430: The Use of Fricke Solutions to Assess Light Dose in Photodynamic Therapy. Med Phys 2006. [DOI: 10.1118/1.2241350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
82
|
Gandolfi L, Catassi C, Garcia S, Modelli IC, Campos D, Pratesi R. Antiendomysial antibody test reliability in children with frequent diarrhea and malnutrition: is it celiac disease? J Pediatr Gastroenterol Nutr 2001; 33:483-7. [PMID: 11698768 DOI: 10.1097/00005176-200110000-00013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the specificity of the immunoglobulin A (IgA) antiendomysial antibody test in the diagnosis of celiac disease in a group of malnourished children with acute diarrhea, chronic diarrhea, or parasitosis, because the reliability of this test has been questioned when applied to this specific group of patients. METHODS Serum IgA level, IgA antiendomysial antibody (EMA) test, and stool examination were performed in 315 children, ranging in age 6 months to 13 years (range, 41 +/- 2.9 months), affected by malnutrition, isolated or in association with diarrhea or parasitosis. Independent of results, 33 children with a strong suspicion of celiac disease, also underwent IgA antitransglutaminase antibody test and jejunal biopsy. RESULTS The EMA test was negative in 313 children, including the 43 with parasitosis, being positive in two patients in whom biopsy disclosed typical celiac mucosal abnormalities (1:157). The 31 children with negative EMA test who underwent biopsy also showed negative antitransglutaminase antibody results. Their biopsies disclosed normal mucosa in 1 patient, variable degree of jejunal atrophy (grade 1 and 2) in 27 patients, and grade 3 abnormalities in 3 patients. One of these three children, showing severe jejunal atrophy, died. The diagnosis of celiac disease was apparently not confirmed by a protracted gluten challenge in the other two children. CONCLUSIONS The specificity of the EMA test seems to be high also in children with chronic malnutrition and diarrhea. However, the possibility of false-negative tests among immunologically compromised children cannot be excluded. In doubtful cases, the gluten challenge is required in malnourished children with clinical picture, biopsy finding, and evolution suggestive of celiac disease.
Collapse
|
83
|
Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19:1759-67. [PMID: 11251007 DOI: 10.1200/jco.2001.19.6.1759] [Citation(s) in RCA: 181] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The NK1-receptor antagonist MK-869 (L-754,030) has demonstrated antiemetic activity in humans receiving chemotherapy. Objectives of the present trial included the first assessment of oral MK-869 plus dexamethasone compared with a 5HT(3) antagonist plus dexamethasone for prevention of acute and delayed emesis after high-dose cisplatin. Furthermore, the study sought to confirm that addition of MK-869 to a 5HT(3) antagonist plus dexamethasone was more effective than just the 5HT(3) antagonist plus dexamethasone for prevention of acute and delayed emesis. METHODS This multicenter, double-blind, parallel-group trial in 351 cisplatin-naïve patients evaluated prevention of acute (0 to 24 hours) and delayed emesis (primary efficacy parameter; days 2 to 5) after cisplatin (> or =70 mg/m(2)). Patients were randomized to four groups (I to IV) (n = number randomized; number evaluable): granisetron (10 microg/kg intravenously) pre-cisplatin followed by placebo on days 2 to 5 (group I) (n = 90; 90); granisetron and MK-869 (400 mg PO [by mouth]) pre-cisplatin, followed by MK-869 (300 mg PO) on days 2 to 5 (group II) (n = 86; 84); MK-869 (400 mg PO) the evening before and pre-cisplatin, followed by MK-869 (300 mg PO) on days 2 to 5 (group III) (n = 89; 88); or MK-869 (400 mg PO) pre-cisplatin, followed by MK-869 (300 mg PO) on days 2 to 5 (group IV) (n = 86; 84). All patients also received dexamethasone (20 mg PO) before cisplatin. Additional medication was available to treat emesis or nausea at any time. RESULTS In the acute period, 57%, 80%, 46%, and 43% of patients were without emesis in groups I, II, III, and IV, respectively (P <.01 for group II v group I). In the delayed period, the proportion of patients without emesis in groups I, II, III, and IV was 29%, 63%, 51%, and 57%, respectively (P <.01 for groups II, III, and IV v group I). The distribution of nausea scores in the delayed period was lower when comparing group II with group I (P <.05 for days 1 to 5 and days 2 to 5). One serious adverse event (dizziness) was rated as possibly related to MK-869. CONCLUSION Once daily oral administration of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin. However, the combination of the 5HT3 antagonist plus dexamethasone was numerically superior to MK-869 plus dexamethasone in reducing acute emesis. Confirming and extending previous findings, the triple combination of a 5HT(3) antagonist, MK-869, and dexamethasone provided the best control of acute emesis.
Collapse
|
84
|
Díliz-Pérez H, Guadalupe Valencia B, Campos D, Díliz-Nava H. [Preservation of hepatocytes in UW and HTK solutions with added fluorocarbons]. REVISTA DE GASTROENTEROLOGIA DE MEXICO 2001; 66:27-31. [PMID: 11464626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
BACKGROUND One of the limitations for hepatocyte transplantation is the short survival of isolated hepatocytes. OBJECTIVE We evaluated the utility of fluorocarbons (PFC) added to University of Wisconsin (UW) and histidine-tryptofane-ketoglutarate (HTK) solutions on hepatocyte preservation. METHOD Rat hepatocytes were isolated by colagenase digestion technique, with a viability greater than 85% measured by tripan blue exclusion. We suspended 1.2 x 10(8) hepatocytes in 20 mL of: HTK solution, HTK with perfluor-n-octane (HTK + PFC), UW solution, and E. Williams medium as control group (CG). Five samples of each group were stored at 4 degrees C for 40 h. We measured Cell viability, large membrane bleb formation and extracellular LDH at 0, 12, 24 and 36 hours. RESULTS Cell viability was lower in the UW at 12 h (p < 0.05) and 24 h (p < 0.05) compared to the rest of the study groups; at 36 h we found no differences in cell viability. There were fewer hepatocytes with large membrane blebs in UW + PFC; compared with the remainder of the solutions, but this difference was only reached statistical significance when compared to UW at 24 h (p < 0.05) and at 36 h (p < 0.05). When comparing groups with or without fluorocarbons LDH levels showed no difference at 0, 12, 24, and 36 h. CONCLUSIONS The present study shows that the addition of fluorocarbons to UW solution diminishes large membrane formation (irreversible damage) and improves cell viability at 12 and 24 h. However, fluorocarbons added to both solutions failed to increase preservation time beyond 24 h.
Collapse
|
85
|
Gershanovich M, Chaudri K, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichard P, O'Higgins NO, Romieu G, Friedrich P, Lassus M. [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. VOPROSY ONKOLOGII 1999; 45:361-8. [PMID: 10532092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens. 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicenter trial. The primary end-point was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrollment of the last patient, while survival was analysed 15 months after the last patients was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Overall objective response rates (complete + partial) of 19.5%, 16.7% and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-estrogens.
Collapse
|
86
|
Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998; 9:639-45. [PMID: 9681078 DOI: 10.1023/a:1008226721932] [Citation(s) in RCA: 192] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens. PATIENTS AND METHODS 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicentre trial. The primary endpoint was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrollment of the last patient, while survival was analysed 15 months after the last patient was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. RESULTS Overall objective response rates (complete + partial) of 19.5%, 16.7% and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Transient nausea was the most frequent event with letrozole (7% on 0.5 mg, 10% on 2.5 mg, 10% on AG), rash with AG (11%, 1% on 0.5 mg, 3% on 2.5 mg letrozole). CONCLUSIONS Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-oestrogens.
Collapse
|
87
|
Possinger K, Gershanovich M, Campos D, Romie G, Lurie H, Bonaventura T, Chaudn H, Homberger U, Bischoff M. Letrozole (FEMARA®), a new potent, selective aromatase inhibitor (AI): Superior to another AI, aminoglutethimlde (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85215-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
88
|
Campos D. [Predictive score of infectious complications on kalazar of child]. J Pediatr (Rio J) 1996; 72:411-4. [PMID: 14688908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
The reports on fifty four children under thirteen years old with visceral leishmaniasis were evaluated to find a prediction criterion for the risk of infectious complications on the course of this disease. The children were divided into two groups according the presence or absence of infectious complications. The statistic model adopted was the Fisher Discriminant Analysis by the method of Wilks. The variables presenting a good discriminant power were: heart rate, white blood cells count, blood lymphocytes count, platelets count and glutamic-oxalacetic transaminase. The discriminant score for the risk of infectious complications in each case was estimated by means of the defined discriminant function, resulting in 75.93% of correct classification in each group, with 80.60% of correct prediction of the risk. This procedure is then valid as a prediction instrument for infectious complications on the course of kalazar in children and may contribute to improve the quality of treatment of this disease.
Collapse
|
89
|
Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14:2552-9. [PMID: 8823335 DOI: 10.1200/jco.1996.14.9.2552] [Citation(s) in RCA: 214] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE Bone metastases are a major cause of morbidity in breast cancer, resulting in complications that include pain, loss of mobility, pathologic fracture, and tumor-induced hypercalcemia (TIH). Inhibition of osteoclast-mediated bone destruction using bisphosphonates represents a promising new management approach. PATIENTS AND METHODS Breast cancer patients with bone metastases were randomly allocated to receive chemotherapy alone (152 patients) or chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1-hour intravenous infusion every 3 weeks (143 patients). Whenever possible, treatment continued until progression of disease (PD) in bone appeared on radiographs or bone scan. Time to PD in bone and pain reduction according to a self-assessment six-point scale were selected as primary end points. PD in bone was verified during extramural review (EMR) of all imaging studies by blinded observers, and these data were used as the main efficacy criterion. Analgesic intake, World Health Organization (WHO) performance status, and complications of bone metastases (radiotherapy, TIH, fractures, orthopedic surgery) were also compared in the two groups. RESULTS AND CONCLUSION At EMR, median time to PD in bone was increased by 48% in patients who received pamidronate (249 v 168 days; P = .02, Wilcoxon test). Marked pain relief, defined as a two-point decrease lasting for > or = 6 weeks, was reported by 44% of pamidronate patients and by 30% of controls (P = .025, chi 2 test). The infusions (median, nine per patient; range, 0 to 39) were well tolerated, with no major toxicities reported. Pamidronate by repeated infusion can significantly slow the progression of bone metastases and reduce attendant morbidity.
Collapse
|
90
|
Campos D. [Validation of therapeutic test in the diagnosis and treatment of Kala-Azar in children]. J Pediatr (Rio J) 1995; 71:266-9. [PMID: 14688993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
The author studied the value of therapeutic test for the diagnosis and treatment of kala-azar in children by comparing two groups of patients. The identification of Leishmania donovani in smears of bone marrow confirmed the diagnosis in all fifty seven patients of the control group. In another group with sixteen children, the diagnosis was based on the successful response to the treatment with meglumine antimonate. In none of the patients of the second group the protozoa was identified and the decision to give the specific treatment was based on epidemiological, clinical, biochemical and hematological criteria for the disease. Statistical analysis was performed by Student t test to compare clinical, biochemical and hematological variables between the groups. None of the differences between the groups was statistically significant, suggesting that the therapeutic test was valid, and all patients who received treatment had kala-azar.
Collapse
|
91
|
Campos D. [Clinical and epidemiological features of Kala-Azar in children]. J Pediatr (Rio J) 1995; 71:261-5. [PMID: 14688992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
The author reviewed the records of 75 patients under thirteen years old, with Visceral Leishmaniasis, admitted in the public hospitals of Brasilia, during the period from January 1982 to June 1991. All children were referred to Brasília hospitals from other states of the country, and most of them from the rural areas of Bahia state. In 78.6% of the patients the diagnosis of Visceral Leishmaniasis was confirmed one to six months after the appearance of the first clinical sign of the disease. The clinical manifestations observed in this study were similar to those previously described in the literature. Moderate to severe malnutrition was present in half of the patients. The laboratory tests showed expected results for the disease. All patients were treated with N-methyl-glucamine, and this therapeutic was successful in 91.4% of the children. The complications more frequently seen were infections and hemorrhage. There were 7 deaths due to pneumonia with respiratory failure and digestive bleeding.
Collapse
|
92
|
Murphy EC, Campos D, Arlinghaus RB. Cell-free synthesis of Rauscher murine leukemia virus "gag" and "env" gene products from separate cellular mRNA species. Virology 1979; 93:293-302. [PMID: 452407 DOI: 10.1016/0042-6822(79)90234-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
93
|
Coria A, Campos D, Treuer C. [Neonatal listeriosis]. REVISTA CHILENA DE PEDIATRIA 1971; 42:13-20. [PMID: 5555747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|